Alpha-1 Acid Glycoprotein as a Biomarker for Subclinical Illness and Altered Drug Binding in Rats

Area of Science:

• Pharmacology and Toxicology
• Biomarker Discovery
• Infectious Disease Models

Background:

• Alpha-1 acid glycoprotein (AGP) is a key drug-binding protein, crucial for determining drug efficacy and toxicity.
• AGP levels increase with infection, but are not well-established in subclinical infection models.
• Accurate AGP measurement is vital for drug development and health surveillance.

Purpose of the Study:

• To establish a subclinical infection model in rats using AGP as a biomarker.
• To evaluate the utility of AGP in health surveillance and outlier identification.
• To inform the characterization of drug candidates in infected models.

Main Methods:

• Dose-response study of Staphylococcus aureus (S. aureus) inoculation in Sprague-Dawley rats.
• Evaluation of plasma AGP levels at various bacterial concentrations and time points.
• Model validation using propranolol to assess AGP's impact on drug pharmacokinetics.

Main Results:

• Plasma AGP significantly elevated on day 2 post-S. aureus inoculation (10^6-10^8 CFU), persisting on day 4 for higher doses.
• No significant AGP increase observed with vehicle control or low-dose S. aureus (10^3 CFU).
• Infection model validated by robust AGP elevations and altered propranolol pharmacokinetics (AUC) in infected rats.

Conclusions:

• AGP serves as a reliable biomarker for subclinical S. aureus infections in rats.
• The established model allows for accurate interpretation of drug pharmacokinetics and pharmacodynamics.
• Consideration of AGP levels is essential for effective drug development and health monitoring.